Apellis Pharma fails primary and secondary endpoints in amyotrophic…

Apellis Pharmaceuticals Inc APLS announced that the Phase 2 MERIDIAN study evaluating systemic Pegcetacoplan in amyotrophic lateral sclerosis (ALS) did not meet its primary endpoint of Combined Assessment of Function and Survival (CAFS). Rank score in week 52. CAFS assesses patients’ clinical outcomes based on survival time and change in ALS Functional Rating […]

Apellis announces 24-month phase 3 post hoc results demonstrating treatment…

Recent analyzes of microperimetry data showed positive trends for both monthly and bimonthly Pegcetacoplan treatment near the GA lesion margin compared to sham treatment These analyzes provide further evidence that slowing the growth of GA lesions with Pegcetacoplan has the potential to preserve visual function The data were presented during an oral presentation at the […]